Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT... Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. 詳細を表示
Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has...
Expanded collaboration to yield greater biopharma access to Personalis’ MRD solution Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences: Piper...
41% Year-over-Year Increase in Revenue Driven by Strong Biopharma Growth of 96% Raising 2024 Revenue Guidance Due to Accelerating Growth Cash Balance of $143.7 Million Extends Expected Runway...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.04 | 53.4031413613 | 3.82 | 7.19 | 3.37 | 3087500 | 5.24941452 | CS |
4 | 2.31 | 65.0704225352 | 3.55 | 7.19 | 3.36 | 1209966 | 4.79315147 | CS |
12 | 0.68 | 13.1274131274 | 5.18 | 7.19 | 3.28 | 869444 | 4.70038661 | CS |
26 | 4.61 | 368.8 | 1.25 | 7.2 | 1.135 | 1180319 | 4.4333253 | CS |
52 | 4.34 | 285.526315789 | 1.52 | 7.2 | 1.12 | 773632 | 3.79155488 | CS |
156 | -9.1 | -60.8288770053 | 14.96 | 14.99 | 0.8906 | 548673 | 3.94651473 | CS |
260 | -3.92 | -40.081799591 | 9.78 | 53.46 | 0.8906 | 563534 | 12.19427391 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約